Suppliers / Bcn Peptides

Bcn Peptides

Spain Updated 9 July 2026

Bcn Peptides is an API manufacturer based in Spain. It holds 24 active US drug master files across a filed portfolio of 14 molecules. Its GMP standing is certified by EMA, US FDA and NCELS (KZ), among 4 authorities. Its most recent recorded inspection, by US FDA, closed on 9 October 2023 as VAI.

24
active US DMFs
0
valid CEPs
3
registered plants 1 with an FDA FEI number
3
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
5 of 5 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 9 October 2023 VAI US FDA
  • 15 March 2019 VAI US FDA
  • 16 January 2015 NAI US FDA
  • 26 April 2012 NAI US FDA
  • 18 March 2010 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Barcelona, Spain Not on file
Spain, Spain 3008205509
Sant Quinti De Mediona, Spain Not on file

What they file, and where

Molecule Regulators Docs
Vasopressin SFDA (Saudi Arabia), US FDA 4
Desmopressin SFDA (Saudi Arabia), US FDA 3
Leuprolide SFDA (Saudi Arabia), US FDA 3
Octreotide SFDA (Saudi Arabia), US FDA 3
Angiotensin Ii US FDA 2
Cetrorelix US FDA 2
Ganirelix US FDA 2
Icatibant US FDA 2
Lanreotide US FDA 2
Nesiritide US FDA 2
Show all 14 molecules on file
Salmon Calcitonin US FDA 2
Tetracosactide US FDA 2
Carbetocin SFDA (Saudi Arabia) 1
Terlipressin SFDA (Saudi Arabia) 1

Also appears on these molecule pages

Cetrorelix API Desmopressin API Ganirelix API Icatibant API Lanreotide API Leuprolide API Octreotide API Terlipressin API Vasopressin API

Filings and GMP by regulator

Regulator Filings GMP certificates
MINSA (CR) 3 None
EMA None 1
US FDA None 1
NCELS (KZ) None 1
AEMPS (ES) None 1

Questions about Bcn Peptides

Does Bcn Peptides hold a US DMF or a CEP?
Bcn Peptides holds 24 active US drug master files. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Bcn Peptides FDA-registered?
One site operated by Bcn Peptides carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Bcn Peptides's last inspection go?
The most recent inspection on record closed on 9 October 2023 as VAI (Voluntary Action Indicated: issues were found but did not warrant regulatory action). 5 inspections are on file.
Where does Bcn Peptides manufacture?
3 registered sites are on record, in Spain (Barcelona, Spain and Sant Quinti De Mediona). Every site is listed on this page with the register it came from.
What does Bcn Peptides make?
14 molecules are on record against Bcn Peptides, including Vasopressin, Desmopressin, Leuprolide and Octreotide. Each links through to that molecule's full manufacturer list.
Which regulators recognise Bcn Peptides's GMP?
Current GMP certificates are on record from EMA, US FDA, NCELS (KZ) and AEMPS (ES). GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Bcn Peptides comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 9 October 2023.

Comparable suppliers

Piramal Pharma shares 7 molecules Auro Peptides shares 6 molecules PolyPeptide shares 5 molecules Hybio Pharmaceutical shares 5 molecules Alp Pharm Beijing shares 4 molecules

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates